Education
About Us
Working with TipRanks
Follow Us
Enovis (ENOV)
NYSE:ENOV
ENOV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$25.47 - $49.83
Previous CloseN/A
Volume391.51K
Average Volume (3M)1.41M
Market Cap
$1.78B
Enterprise Value$3.35B
Total Cash (Recent Filing)$44.07M
Total Debt (Recent Filing)$1.46B
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Oct 30, 2025EPS Estimate
0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.79
Shares Outstanding57,159,800
10 Day Avg. Volume1,021,887
30 Day Avg. Volume1,410,256
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.88
Enterprise Value/Revenue1.53
Enterprise Value/Gross Profit2.57
Enterprise Value/Ebitda-7.27
Forecast
1Y Price Target
$49.89Price Target Upside63.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
Financial GuidanceENOV raised its FY25 guidance across revenue, organic growth, EBITDA, and EPS, supported by operational execution, FX tailwinds, and decreased expected tariff impacts.
Revenue And GrowthEnovis reported Q2 revenues above expectations, with strong performance across various segments, indicating robust business momentum.
ValuationThe stock is trading at less than half the valuation of its mid-cap MedTech peers, suggesting it is significantly undervalued.
Bears Say
Organic Growth SlowdownOrganic revenue growth slowed to 5.1% in 2Q25 from 10.4% in 1Q25.
Peer Valuation ImpactThe price target is lowered to $49 due to peer multiple contraction.
Product Launch DelaysThe next-gen ARVIS launch has been delayed by approximately 6 months to incorporate enhancements, although surgeon excitement around the platform remains high.
Enovis News
ENOV FAQ
What was Enovis’s price range in the past 12 months?
Enovis lowest stock price was $25.46 and its highest was $49.83 in the past 12 months.
What is Enovis’s market cap?
Enovis’s market cap is $1.78B.
When is Enovis’s upcoming earnings report date?
Enovis’s upcoming earnings report date is Oct 30, 2025 which is in 61 days.
How were Enovis’s earnings last quarter?
Enovis released its earnings results on Aug 07, 2025. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.719 by $0.071.
Is Enovis overvalued?
According to Wall Street analysts Enovis’s price is currently Undervalued.
Does Enovis pay dividends?
Enovis does not currently pay dividends.
What is Enovis’s EPS estimate?
Enovis’s EPS estimate is 0.65.
How many shares outstanding does Enovis have?
Enovis has 57,159,800 shares outstanding.
What happened to Enovis’s price movement after its last earnings report?
Enovis reported an EPS of $0.79 in its last earnings report, beating expectations of $0.719. Following the earnings report the stock price went up 10.714%.
Which hedge fund is a major shareholder of Enovis?
Currently, no hedge funds are holding shares in ENOV
Enovis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.89 (63.09% Upside)
$49.89 (63.09% Upside)
Blogger Sentiment
Bullish
ENOV Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $463.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 18.7%
Last 30 Days ▲ 34.0%
Last 30 Days ▲ 34.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.82%
12-Months-Change
Fundamentals
Return on Equity
-28.31%
Trailing 12-Months
Asset Growth
-7.73%
Trailing 12-Months
Company Description
Enovis
Enovis (ENOV) is a global medical technology company focused on developing innovative solutions for the orthopedic and rehabilitation markets. The company specializes in a range of products, including surgical implants, orthopedic devices, and digital health solutions designed to enhance patient outcomes and streamline clinical workflows. Enovis operates in various sectors including surgical instruments, post-operative care, and rehabilitation technologies, leveraging advanced materials and technology to improve patient mobility and recovery.
ENOV Company Deck
ENOV Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Enovis was generally positive, with strong revenue and margin growth, successful product launches, and improved financial guidance. However, there were challenges such as delays in the Arvis product launch, flat growth in the U.S. hip and knee segment, and tariff-related headwinds. Despite these setbacks, the company's overall performance and outlook are optimistic.View all ENOV earnings summariesENOV Stock 12 Month Forecast
Average Price Target
$49.89
▲(63.09% Upside)
Technical Analysis
Ownership Overview
2.12% Insiders
45.74% Mutual Funds
0.64% Other Institutional Investors
21.80% Public Companies and
Individual Investors